Diagnocure announces the formation of a new Strategic Advisory Board

06-Aug-2008

Diagnocure Inc. announced that four prominent colorectal cancer key opinion leaders have agreed to serve on the Strategic Advisory Board of its wholly owned subsidiary, DiagnoCure oncology Laboratories.

The Strategic Advisory Board is composed of Dr. Edith Mitchell, MD, FACP, Clinical Professor of Medicine & Medical Oncology at Jefferson Kimmel Cancer Center; Dr. Stanley R. Hamilton, MD, Professor and Head, Division of Pathology & Laboratory Medicine at the MD Anderson Cancer Center; Dr. Daniel J. Sargent, Ph.D., Professor of Statistics and Oncology and Director of Cancer Statistics at Mayo Clinic; Dr. Martin R. Weiser, MD, Surgical Oncologist at the Memorial Sloan-Kettering Cancer Center. Their mandate consists of advising the Company on a number of issues related to Previstage(TM) GCC and the Company's commercialization efforts.

"DiagnoCure is proud to count on these top renowned specialists to provide critical input on the positioning of the test and its future improvements," stated John Schafer, President and CEO of DiagnoCure.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances